• Publications
  • Influence
A predictive model for aggressive non-Hodgkin's lymphoma.
BACKGROUND Although many patients with intermediate-grade or high-grade (aggressive) non-Hodgkin's lymphoma are cured by combination chemotherapy, the remainder are not cured and ultimately die ofExpand
  • 3,886
  • 51
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
BACKGROUND AND METHODS MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) has been the standard treatment for Hodgkin's disease for almost 20 years. In a randomized, multicenter trial,Expand
  • 1,019
  • 41
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.
A new modification of our detergent technique for the preparation of nuclei for flow cytometric DNA analysis is described. The attainment of low coefficients of variation of the peaks and ofExpand
  • 1,673
  • 25
Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards.
Determination of nuclear DNA content by flow cytometry requires comparison with a reference standard. The use of external standards such as lymphocytes or granulocytes is time-consuming andExpand
  • 382
  • 11
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study
A randomized comparison of the relative efficacy and toxicity of daunorubicin (DNR) at 30 or 45 mg/sq m or adriamycin (ADM) at 30 mg/sq m, given on the first 3 days of a 7-day continuous infusion ofExpand
  • 414
  • 8
Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment.
Meningeal involvement (MI) by non-Hodgkin's lymphoma (NHL) was seen in 38/602 patients (6.3%). In relation to histologic subtype the frequency of MI was: Follicular small cleaved and mixed cell 2/128Expand
  • 77
  • 4
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
By Kanti R. Rai, James F. Holland, Oliver J. Glidewell, Vivian Weinberg, Kurt Brunner, J. P. Obrecht, Harvey D. Preisler, Ismat W. Nawabi, David Prager, Robert W. Carey, M. Robert Cooper, FaridExpand
  • 131
  • 4
Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma.
Abstract We observed nine cases of transitional-cell carcinoma of the urinary bladder among patients who had had long-term treatment of other cancers with cyclophosphamide. Seven of the bladderExpand
  • 134
  • 3
Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.
Between 1974 and 1977, the Cancer and Leukemia Group B (CALGB) initiated four studies which address current major questions in the therapy for Hodgkin's disease. The efficacy of chemotherapy alone asExpand
  • 48
  • 3